CAPhO Podcast: ISOPP’s 2023 Symposium Highlights

Presented by CAPhO (Canadian Association of Pharmacy in Oncology)

CAPhO Connections Podcast on ISOPP’s 2023 Symposium Highlights

This month's episode of the CAPhO Connections Podcast focuses on the 2023 International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium in Seville, Spain.

Hear the highlights of the Symposium from Lauren Hutton, who brings back a piece of Spain as well as lots of practice-advancing insights in this post-ISOPP recap.

Episode 11's Learning Objectives:
•    Provides an overview of the oncology pharmacy burnout plenary session and shares major takeaways from the presentation (including resources)
•    Discusses the technology developments influencing your future of pharmacy practice (from those presented at the conference)
•    Discusses the therapeutic innovations and research presented at ISOPP 2023
•    Highlights the incredible learning opportunities made possible by the CAPhO travel grant program.

CAPhO Connections Podcast Series keeps the oncology pharmacy community informed on matters affecting you and updated on CAPhO’s news related to education, awards, advocacy, and research. To listen to the CAPhO Connections Podcast on Apple devices, check out thier Apple Podcast page, or visit the CAPhO Connections Podcast page to access podcasts and learn more.


Guest Profile: Lauren Hutton, CAPhO Member

Lauren Hutton is the Clinical Coordinator for Oncology Pharmacy at Nova Scotia Health – Central Zone. Lauren completed a BSc (Pharmacy) at Dalhousie University, her hospital residency at The Ottawa Hospital and subsequently went on to complete her PharmD at the University of Toronto. 

Lauren has been practicing in oncology for six years. Her oncology clinical practice areas have included ambulatory medical oncology, acute inpatient palliative oncology, and multiple myeloma ambulatory care. Lauren’s current clinical practice is as an inter-disciplinary member of a medical oncology team where she provides care to patients living with prostate cancer receiving treatment with oral anti-cancer therapy.